✨ Free AI Report
Keros Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Keros Therapeutics, Inc.
Research Preview

Keros Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. T...

Analyst-debate audio for Keros Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Keros Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Keros Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Keros is positioned as an attractive clinical-stage biotech with near-term catalysts in DMD and neuromuscular disease, supported...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-Stage Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Keros Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Keros Therapeutics, Inc. Overview

Pro stress-test →

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. The company is a leader in understanding TGF-ß proteins, which are master regulators of growth, repair and maintenance of tissues including blood, bone, skeletal muscle, adipose and heart tissue.

Strategic Profile

Pro stress-test →

Keros' lead product candidate is rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while its most advanced product candidate, elritercept, is being developed for cytopenias in myelodysplastic syndrome and myelofibrosis patients. The company posted a net loss of $7.3 million in Q3 2025 versus $53.0 million in Q3 2024, driven by revenue recognized under its license agreement with Takeda.

Competitive Landscape

Pro stress-test →

The DMD space is particularly competitive and complex; many patients are treated with corticosteroids, and Sarepta Therapeutics is a formidable competitor with exon-skipping therapies including Exondys 51, Vyondys 53 and Amondys 45. The company faces increased competition from both established and emerging therapies that could dilute market share.

Industry Context

Keros Therapeutics, Inc. operates in Biopharmaceutical / Clinical-Stage Therapeutics.

Key facts

Founded: 2015 · Headquarters: Lexington, Massachusetts, US · Market cap: $620.3M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Keros Therapeutics, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Keros Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Exondys 51 / Vyondys 53 / Amondys 45Exon-skipping therapies for DMD→TranslarnaPreviously approved DMD therapy (conditional authorization)→Various TGF-β targeting therapiesCompeting TGF-beta pathway modulators→

Compare Keros Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Keros Therapeutics, Inc. operates in Biopharmaceutical / Clinical-Stage Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical-Stage Therapeutics research →
NEW · MCP server

Ask your AI assistant about Keros Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Keros Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Keros Therapeutics, Inc. do this quarter?”
“Is Keros Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Keros Therapeutics, Inc. do?+
Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. T...
What is Keros Therapeutics, Inc.'s Cyborg Score?+
Keros Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Keros Therapeutics, Inc.'s main competitors?+
Named competitors include Exondys 51 / Vyondys 53 / Amondys 45, Translarna, Various TGF-β targeting therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Keros Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Keros Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Keros Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score